Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pirfenidone for chronic progressive multiple sclerosis.

J E Walker1, S B Margolin

  • 1Board Certified Psychiatry and Neurology, Dallas, Texas 75230, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|November 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of a Nerve Gas Detoxifying Enzyme from Squid and from Pseudomonas diminuta.

The Biological bulletin·2017
Same author

A PHYSICO-CHEMICAL STUDY OF THE MECHANICAL PROPERTIES OF LOW AND INTERMEDIATE MOISTURE FOODS.

Journal of texture studies·2017
Same author

A Commensal Strain of Staphylococcus epidermidis Overexpresses Membrane Proteins Associated with Pathogenesis When Grown in Biofilms.

The Journal of membrane biology·2015
Same author

Nucleotide sequences of the genes for the alpha, beta and epsilon subunits of wheat chloroplast ATP synthase.

Plant molecular biology·2013
Same author

Mitochondrial nucleoid interacting proteins support mitochondrial protein synthesis.

Nucleic acids research·2012
Same author

Human C4orf14 interacts with the mitochondrial nucleoid and is involved in the biogenesis of the small mitochondrial ribosomal subunit.

Nucleic acids research·2012

Pirfenidone shows promise in treating secondary progressive multiple sclerosis by reducing inflammation and stabilizing neurological decline. This pilot study suggests potential for a new therapeutic option, warranting further investigation.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Secondary progressive multiple sclerosis (SPMS) treatments are currently inadequate for halting disease progression.
  • Tumor Necrosis Factor-alpha (TNF-alpha) is implicated in demyelination, a key pathological process in MS.
  • Pirfenidone is a novel drug that inhibits TNF-alpha synthesis and receptor activity.

Purpose of the Study:

  • To evaluate the safety and efficacy of oral pirfenidone in patients with SPMS.
  • To assess pirfenidone's impact on neurological disability and disease progression over two years.

Main Methods:

  • An open-label, 2-year pilot study involving 20 SPMS patients.
  • Patients received oral pirfenidone, with outcomes assessed using primary and secondary measures.

Related Experiment Videos

  • Magnetic resonance imaging (MRI) was used to monitor new lesion formation.

    • Main Results:

    • 70% of patients completed the 2-year study; most showed improvement or stabilization within 3 months, sustained throughout.
    • No significant drug-related adverse reactions were reported in the remaining patients.
    • MRI scans showed no new lesions, suggesting pirfenidone may halt disease activity.

    Conclusions:

    • Pirfenidone demonstrated potential in stabilizing or improving neurological function in SPMS patients.
    • The drug appears to protect against disease progression and lesion development.
    • Further large-scale, placebo-controlled trials are recommended to confirm these findings.